| Grab Sources And More: Presentation. Fact Sheet. Website. -----
And as I mentioned above, (Nasdaq: SILO) has several potential catalysts to consider this moment. Check them out:
No. 1 SILO Potential Catalyst - Could A Low Float Lead To Heightened Volatility?
According to the Yahoo Finance website, SILO has a fairly low float.
In fact, the website reports this profile has approximately 4.29Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the first half of 2025, could it create a near term spark? -----
No. 2 SILO Potential Catalyst - Positive Results Could Draw Serious Buzz To Company's SP-26 Implant.
Silo Pharma’s SP-26 Ket-a-mine Implant Meets All Endpoints in Fibromyalgia Study
— Successfully demonstrates strong tolerability, sustained drug release and safety
SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ket-a-mine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.
All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation.
“Our team is pleased to report that SP-26 met all expectations in this preclinical study,” said Eric Weisblum, CEO of Silo Pharma. “We believe these results support the advancement of SP-26 as a next-generation therapeutic for fibromyalgia, combining the proven efficacy of ket-a-mine with the safety and convenience of extended-release delivery.”
...
“SP-26 has been designed to offer a new approach to pain management by providing sustained, sub-psych-e-delic levels of ket-a-mine in an abuse-deterrent format,” Weisblum added. “Preclinical SP-26 research overall has focused on ensuring that the safety profile of SP-26 aligns with FDA requirements for potential at-home therapeutic designation. If approved, SP-26 could become the first at-home injectable ket-a-mine-based therapeutic.”
Read the full article here. -----
No. 3 SILO Potential Catalyst - SILO Expands IP Portfolio With Key Patent Application For SPC-14.
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.
The patent, titled “Compositions and Methods for the Treatment of Alzheimer’s Disease and Other Neurogenerative Disease,” covers SPC-14’s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD. By targeting the two receptor molecules, the drug has shown efficacy against luteinizing hormone (LH) in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety).
“Early pre-clinical studies of SPC-14 have demonstrated the drug’s potential to improve and restore cognitive memory function,” said Eric Weisblum, CEO of Silo. “The patent application for SPC-14 supports our intellectual property strategy for strong security and protection of each of our drug platforms.”
...
Read the full article here. -----
No. 4 SILO Potential Catalyst - A New Milestone Reached! First Dosing Completed In SPC-15 Study.
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials
SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
“This IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an IND for SPC-15,” said Eric Weisblum, CEO of Silo. “We are following the FDA’s helpful responses to our pre-IND submission, which provide a clear path to an IND submission to first-in-human clinical studies.” ...
Read the full article here. -----
No. 5 SILO Potential Catalyst - SILO Encouraged By Early Initial Data From Its SP-26 Animal Study.
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
No serious side effects or discomfort observed
Final safety and absorption data expected in March 2025
SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ket-a-mine extended-release rods when implanted subcutaneously. The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia.
The launch of our non-GLP study in December 2024 marked the first small animal testing of SP-26, a key preclinical milestone. Implantation (dosing) was completed in the first week of January 2025 and no animals experienced serious side effects or discomfort. Absorption, distribution, metabolism, and excretion (ADME) testing is nearing completion and final safety, and pharmacokinetic reports are expected in March 2025.
“We are encouraged by the early initial data from the SP-26 animal study, with no abnormal clinical observations reported so far,” said Eric Weisblum, CEO of Silo. “We believe that a successful final outcome would provide clear, actionable data for validating the advancing of SP-26 as a potential treatment for chronic pain.”
Read the full article here. -----
(Nasdaq: SILO) Recap - 5 Potential Catalysts Lead The Way
No. 1 - Could A Low Float Lead To Heightened Volatility?
No. 2 - Positive Results Could Draw Serious Buzz To Company's SP-26 Implant.
No. 3 - SILO Expands IP Portfolio With Key Patent Application For SPC-14.
No. 4 - A New Milestone Reached! First Dosing Completed In SPC-15 Study.
No. 5 - SILO Encouraged By Early Initial Data From Its SP-26 Animal Study. -----
Coverage has been officially initiated on Silo Pharma, Inc. (Nasdaq: SILO). Be on the lookout for more info coming soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/13/2025 and ending on 05/14/2025 to publicly disseminate information about (SILO:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid seventy eight thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (SILO:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/silo-9f6mx/#details | 
Tidak ada komentar:
Posting Komentar